Kala Pharmaceuticals Inc (NASDAQ:KALA) – Equities researchers at Wedbush decreased their FY2017 earnings estimates for Kala Pharmaceuticals in a research report issued to clients and investors on Tuesday. Wedbush analyst L. Moussatos now expects that the company will post earnings per share of ($2.72) for the year, down from their previous estimate of ($2.28). Wedbush currently has a “Buy” rating and a $46.00 target price on the stock. Wedbush also issued estimates for Kala Pharmaceuticals’ Q4 2017 earnings at ($0.43) EPS, FY2018 earnings at ($2.10) EPS and FY2019 earnings at ($1.51) EPS.

Kala Pharmaceuticals (NASDAQ:KALA) last announced its quarterly earnings results on Tuesday, November 7th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.14).

Several other brokerages have also commented on KALA. J P Morgan Chase & Co set a $35.00 price target on shares of Kala Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, November 19th. Zacks Investment Research lowered shares of Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Oppenheimer started coverage on shares of Kala Pharmaceuticals in a research note on Tuesday, August 15th. They set an “outperform” rating and a $46.00 price objective on the stock. Wells Fargo & Company started coverage on shares of Kala Pharmaceuticals in a research note on Monday, August 14th. They set an “outperform” rating and a $24.00 price objective on the stock. Finally, Bank of America started coverage on shares of Kala Pharmaceuticals in a research note on Monday, August 14th. They set a “buy” rating and a $33.00 price objective on the stock. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. Kala Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $36.80.

Shares of Kala Pharmaceuticals (KALA) opened at $19.02 on Friday. Kala Pharmaceuticals has a 12 month low of $13.51 and a 12 month high of $26.75. The company has a current ratio of 11.00, a quick ratio of 11.00 and a debt-to-equity ratio of 0.14.

A number of institutional investors have recently bought and sold shares of the business. Orbimed Advisors LLC acquired a new position in Kala Pharmaceuticals in the third quarter worth approximately $54,251,000. Caxton Corp acquired a new position in Kala Pharmaceuticals in the third quarter worth approximately $12,430,000. Victory Capital Management Inc. acquired a new position in Kala Pharmaceuticals in the third quarter worth approximately $12,414,000. OxFORD Asset Management LLP acquired a new position in Kala Pharmaceuticals in the third quarter worth approximately $4,374,000. Finally, JPMorgan Chase & Co. acquired a new position in Kala Pharmaceuticals in the third quarter worth approximately $4,037,000. Hedge funds and other institutional investors own 62.96% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Kala Pharmaceuticals Inc Forecasted to Earn FY2017 Earnings of ($2.72) Per Share (KALA)” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/08/kala-pharmaceuticals-inc-forecasted-to-earn-fy2017-earnings-of-2-72-per-share-kala.html.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Receive News & Ratings for Kala Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.